In order to address the core research questions of this project the ADDUCE Consortium was established, an interdisciplinary team with a diversity of experiences and clinical and research skills including drug safety, neuropsychiatry, neuropsychology, pharmacology, cardiology, statistics and project management. The ADDUCE team will have the skills and experience necessary to generate high quality data on the longterm safety of methylphenidate in patients with ADHD and to disseminate the findings to the scientific and professional community, national and international stakeholders and patients in the most appropriate and effective way.
 
The coordinator of the ADDUCE project is dr. D. Coghill / University of Dundee (UNIVDUN), UK.
Subpage
SoP
UCL School of Pharmacy
Subpage
RUNMC
Radboud University Nijmegen Medical Centre
Subpage
CIMH
Central Institute of Mental Health
Subpage
UNIVDUN
University of Dundee
Subpage
UNOTT
University of Nottingham
Subpage
UKAACHEN
Universitaetsklinikum Aachen
Subpage
Subpage
KU Leuven
UPC‐KU Leuven: University Psychiatric Centre - Katholieke Universiteit Leuven
Subpage
UNICA
Università degli Studi di Cagliari
Subpage
INSERM
Institut National pour la Santé et la Recherche Biomédicale
Subpage
EUNETHYDIS
European Network for Hyperkinetic Disorders
Subpage
VCAH
VADASKERT Child and Adolescent Psychiatry Hospital and Outpatient Clinic
Subpage
THERAKIND
THERAKIND
Subpage
ECH
Evelina Children’s Hospital, Guy’s & St Thomas’ Trust
Subpage
Subpage

News

The fifth ADDUCE Newsletter is now available!

Here, you can read about the finalisation of the project,

the European Medicines Agency and General Assembly meetings

and the dissemination of the results!

The fourth ADDUCE Newsletter is available!
 
In this newsletter, you can find some information on the final recruitment status of the 2 main studies:
- the prospective open-label methylphenidate pharmacovigilance study

- the long-term cardiascular effects of methylphenidate use
 
Also, you can read about the future plans of the project!

More than 1500 children, adolescents and adults across all Europe already took part in our study! Thanks to them, we have already gathered lots of information so we can know a lot more about methylphenidate than ever before! 

 

Did you participate in the ADDUCE studies and are you curious about the latest news on the project?

Here you can find some information!

News for children, April 2015

News for adolescents, April 2015

News for parents, April 2015

The third ADDUCE Newsletter is available!
 

Read more about the ADDUCE studies:

- the prospective open-label methylphenidate pharmacovigilance study: recruitment status and spin-
off studies
- the long-term cardiovascular effects of methylphenidate use: study design and participation
 

and much more in the ADDUCE Newsletter 3, March 2015

 

The second ADDUCE Newsletter is available!
Read more about the 2 main ADDUCE studies:

  • WP3: prospective open-label methylphenidate
    pharmacovigilance study
  • WP8: long-term cardiovascular effects of methylphenidate use

and much more in the ADDUCE Newsletter 2, February 2013

Events

16 - 19 OCTOBER 2016:

4rd EUNETHYDIS International Conference on ADHD, Berlin - Germany
from basis neuroscience to optimised clinical care

17 & 18 APRIL 2016:

ADDUCE Consortium meeting, London - UK

28 - 31 MAY 2015:

5th World Congress on ADHD: from Child to Adult Disorder, Glasgow - Scotland

20 & 21 APRIL 2015:

ADDUCE Consortium meeting, Salina - Italy

21 - 24 MAY 2014:

3rd EUNETHYDIS International Conference on ADHD, Istanbul - Turkey
ADHD and related disorders

19 & 20 MAY 2014:

ADDUCE Consortium meeting, Istanbul - Turkey

3 - 6 OCTOBER 2013:

23rd EUNETHYDIS Network Meeting, Prague Czech Republic
A meeting of the European Network of Hyperkinetic Disorders

6 - 9 JUNE 2013:            

4th World Congress on ADHD: from Childhood to Adult Disease, Milan - Italy

4 & 5 JUNE 2013:

ADDUCE Consortium meeting, Milan - Italy

 6 & 7 JUNE 2012:            

ADDUCE Consortium meeting, Cagliari - Italy

23 MAY 2012:

2nd EUNETHYDIS International Conference on ADHD, Barcelona - Spain